生物學標志物在滲出性胸腔積液診斷的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

陳小蓉 ¹ ,  曾惠清 ^1,2 , 王洺輝 ¹ , 余慧蓮 ² , 黃秋芬 ¹ , 蔡芋晴 ¹ , 李琪 ²

1. ;
2. ;

Corresponding?author：

曾惠清, Email: 13606080893@139.com

Keywords：

DOI：

10.7507/1671-6205.201910099

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 陳小蓉, 曾惠清, 王洺輝, 余慧蓮, 黃秋芬, 蔡芋晴, 李琪. 生物學標志物在滲出性胸腔積液診斷的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(2): 148-152. doi: 10.7507/1671-6205.201910099 Copy

1.	Porcel JM, Esquerda A, Vives M, et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol, 2014, 50(5): 161-165.
2.	鄭建, 歐勤芳, 劉袁媛, 等. 結核性胸膜炎患者結核特異性 T 淋巴細胞的免疫應答及其遷徙作用. 中華傳染病雜志, 2013, 31(12): 715-718.
3.	Palma RM, Bielsa S, Esquerda A, et al. Diagnostic accuracy of pleural fluid adenosine deaminase for diagnosing tuberculosis. Meta-analysis of Spanish studies. Arch Bronconeumol, 2019, 55(1): 23-30.
4.	Jeon D. Tuberculous pleurisy: an update. Tuberc Respir Dis (Seoul), 2014, 76(4): 153-159.
5.	Porcel JM, Esquerda A, Bielsa S. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med, 2010, 21(5): 419-423.
6.	Aggarwal AN, Agarwal R, Sehgal IS, et al. Adenosine deaminase for diagnosis of tuberculous pleural effusion: a systematic review and meta-analysis. PLoS One, 2019, 14(3): e0213728.
7.	Bielsa S, Palma R, Pardina M, et al. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis, 2013, 17(1): 85-89.
8.	Ye ZJ, Xu LL, Zhou Q, et al. Recruitment of IL-27-producing CD4⁺ T cells and effect of IL-27 on pleural mesothelial cells in tuberculous pleurisy. Lung, 2015, 193(4): 539-548.
9.	Li M, Zhu W, Khan R, et al. Accuracy of interleukin-27 assay for the diagnosis of tuberculous pleurisy: a PRISMA-compliant meta-analysis. Medicine (Baltimore), 2017, 96(50): e9205.
10.	Liu Q, Yu YX, Wang XJ, et al. Diagnostic accuracy of interleukin-27 between tuberculous pleural effusion and malignant pleural effusion: a meta-analysis. Respiration, 2018, 95(6): 469-477.
11.	Wang W, Zhou Q, Zhai K, et al. Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis. Thorax, 2018, 73(3): 240-247.
12.	Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest, 2007, 131(4): 1133-1141.
13.	Li ZZ, Qin WZ, Li L, et al. Accuracy of enzyme-linked immunospot assay for diagnosis of pleural tuberculosis: a meta-analysis. Genet Mol Res, 2015, 14(3): 11672-11680.
14.	Aggarwal AN, Agarwal R, Gupta D, et al. Interferon gamma release assays for diagnosis of pleural tuberculosis: a aystematic review and meta-analysis. J Clin Microbiol, 2015, 53(8): 2451-2459.
15.	Enz N, Fragoso F, Gamrekeli A, et al. Carcinoembryonic antigen-positive pleural effusion in early stage non-small cell lung cancer without pleural infiltration. J Thorac Dis, 2018, 10(5): E340-E343.
16.	Woo CG, Son SM, Han HS, et al. Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. J Thorac Dis, 2018, 10(8): 4931-4939.
17.	Tozzoli R, Basso SM, D'Aurizio F, et al. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: a prospective study and literature review. Clin Biochem, 2016, 49(16-17): 1227-1231.
18.	周曉明, 康大海, 侯剛, 等. 胰島素樣生長因子結合蛋白 2 和癌胚抗原對惡性胸腔積液與結核性胸腔積液的鑒別診斷價值分析. 實用心腦肺血管病雜志, 2017, 25(1): 95-98.
19.	Nguyen AH, Miller EJ, Wichman CS, et al. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res, 2015, 166(5): 432-439.
20.	陳曉波, 張琳, 徐冉冉. 腫瘤標志物 CA153、CA125 檢驗在肺癌診斷中的應用價值. 中國醫藥指南, 2018, 16(18): 142-143.
21.	Chen Y, Mathy NW, Lu HD. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
22.	Gu Y, Zhang M, Li GH, et al. Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax. Chin Med J (Engl), 2015, 128(3): 305-309.
23.	陳先夢, 孫耕耘. 血管內皮生長因子對惡性胸腔積液診斷價值的 Meta 分析. 中華肺部疾病雜志(電子版), 2017, 10(1): 29-34.
24.	Wu DW, Chang WA, Liu KT, et al. Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion. Oncol Lett, 2017, 14(3): 3657-3662.
25.	Mohajeri A, Sanaei S, Kiafar F, et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering. Adv Pharm Bull, 2017, 7(1): 21-34.
26.	Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab, 2006, 290(6): E1253-E1261.
27.	Wali A, Morin PJ, Hough CD, et al. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer, 2005, 48(1): 19-29.
28.	Tsuji S, Tsuura Y, Morohoshi T, et al. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br J Cancer, 2010, 103(4): 517-523.
29.	B?ger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget, 2016, 7(17): 24269-24283.
30.	Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol, 2016, 17(6): 717-726.
31.	Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget, 2015, 6(38): 41228-41236.
32.	Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol, 2015, 1(9): 1319-1323.
33.	王鵬. 血清可溶性分子 B7-H4 檢測在非小細胞肺癌中的應用. 檢驗醫學, 2013, 28(12): 1140-1141.
34.	冀玉珍, 劉曉良, 侯淼. 可溶性程序性死亡分子配體 1 在肺癌胸腔積液中的水平及臨床意義. 檢驗醫學, 2017, 32(2): 99-103.
35.	張雪漫, 王廷杰. 46 例膿胸的臨床分析和診治體會. 臨床肺科雜志, 2005, 10(2): 234.
36.	趙俊, 陳毅斐. 血清 CRP、ADA、SAA 聯合檢測在鑒別感染性胸腔積液中的價值. 醫學新知雜志, 2017, 27(5): 453-455.
37.	Garcia-Pachon E, Soler MJ, Padilla-Navas I, et al. C-reactive protein in lymphocytic pleural effusions: a diagnostic aid in tuberculous pleuritis. Respiration, 2005, 72(5): 486-489.
38.	Porcel JM, Bielsa S, Esquerda A, et al. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med, 2012, 23(5): 447-450.
39.	黃建達, 蔡挺. C 反應蛋白、觸珠蛋白在胸腔積液鑒別診斷中的價值. 臨床內科雜志, 2001, 18(3): 192-193.
40.	Porcel JM. Pleural fluid tests to identify complicated parapneumonic effusions. Curr Opin Pulm Med, 2010, 16(4): 357-361.
41.	陳孝謙, 汪錚, 李秀. 血清降鈣素原對滲出性胸腔積液病因的鑒別價值. 臨床肺科雜志, 2013, 18(8): 1446-1448.
42.	Lin MC, Chen YC, Wu JT, et al. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest, 2009, 136(1): 205-211.
43.	黃宇筠, 黃鑫炎, 羅益鋒, 等. HS-CRP、PCT 在鑒別類肺炎性與結核性胸腔積液的研究. 實用醫學雜志, 2013, 29(22): 3666-3667.
44.	邱躍靈, 麥轉英. 降鈣素原與 CA125 聯合檢測對結核性胸腔積液的診斷價值. 臨床肺科雜志, 2012, 17(9): 1640-1641.
45.	He C, Wang B, Li D, et al. Performance of procalcitonin in diagnosing parapneumonic pleural effusions: a clinical study and meta-analysis. Medicine (Baltimore), 2017, 96(33): e7829.
46.	Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9(6): 425-434.
47.	Lee J, Lee SY, Lim JK, et al. Radiologic and laboratory differences in patients with tuberculous and parapneumonic pleural effusions showing non-lymphocytic predominance and high adenosine deaminase levels. Infection, 2015, 43(1): 65-71.
48.	鄢斌, 劉軍. 聯合檢測血清及胸水 LDH、ADA、CEA、CA153 對胸水性質的鑒別價值. 現代醫藥衛生, 2009, 25(10): 1505-1507.
49.	Tamiya H, Mitani A, Saito A, et al. Exosomal microRNA expression profiling in patients with lung adenocarcinoma-associated malignant pleural effusion. Anticancer Res, 2018, 38(12): 6707-6714.
50.	Zennaro L, Vanzani P, Nicolè L, et al. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: a route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers. Cancer Cytopathol, 2017, 125(5): 341-348.
51.	Wang C, Peng J, Kuang Y, et al. Metabolomic analysis based on ¹H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion. Mol Med Rep, 2017, 16(2): 1147-1156.

1. Porcel JM, Esquerda A, Vives M, et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol, 2014, 50(5): 161-165.
2. 鄭建, 歐勤芳, 劉袁媛, 等. 結核性胸膜炎患者結核特異性 T 淋巴細胞的免疫應答及其遷徙作用. 中華傳染病雜志, 2013, 31(12): 715-718.
3. Palma RM, Bielsa S, Esquerda A, et al. Diagnostic accuracy of pleural fluid adenosine deaminase for diagnosing tuberculosis. Meta-analysis of Spanish studies. Arch Bronconeumol, 2019, 55(1): 23-30.
4. Jeon D. Tuberculous pleurisy: an update. Tuberc Respir Dis (Seoul), 2014, 76(4): 153-159.
5. Porcel JM, Esquerda A, Bielsa S. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med, 2010, 21(5): 419-423.
6. Aggarwal AN, Agarwal R, Sehgal IS, et al. Adenosine deaminase for diagnosis of tuberculous pleural effusion: a systematic review and meta-analysis. PLoS One, 2019, 14(3): e0213728.
7. Bielsa S, Palma R, Pardina M, et al. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis, 2013, 17(1): 85-89.
8. Ye ZJ, Xu LL, Zhou Q, et al. Recruitment of IL-27-producing CD4⁺ T cells and effect of IL-27 on pleural mesothelial cells in tuberculous pleurisy. Lung, 2015, 193(4): 539-548.
9. Li M, Zhu W, Khan R, et al. Accuracy of interleukin-27 assay for the diagnosis of tuberculous pleurisy: a PRISMA-compliant meta-analysis. Medicine (Baltimore), 2017, 96(50): e9205.
10. Liu Q, Yu YX, Wang XJ, et al. Diagnostic accuracy of interleukin-27 between tuberculous pleural effusion and malignant pleural effusion: a meta-analysis. Respiration, 2018, 95(6): 469-477.
11. Wang W, Zhou Q, Zhai K, et al. Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis. Thorax, 2018, 73(3): 240-247.
12. Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest, 2007, 131(4): 1133-1141.
13. Li ZZ, Qin WZ, Li L, et al. Accuracy of enzyme-linked immunospot assay for diagnosis of pleural tuberculosis: a meta-analysis. Genet Mol Res, 2015, 14(3): 11672-11680.
14. Aggarwal AN, Agarwal R, Gupta D, et al. Interferon gamma release assays for diagnosis of pleural tuberculosis: a aystematic review and meta-analysis. J Clin Microbiol, 2015, 53(8): 2451-2459.
15. Enz N, Fragoso F, Gamrekeli A, et al. Carcinoembryonic antigen-positive pleural effusion in early stage non-small cell lung cancer without pleural infiltration. J Thorac Dis, 2018, 10(5): E340-E343.
16. Woo CG, Son SM, Han HS, et al. Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. J Thorac Dis, 2018, 10(8): 4931-4939.
17. Tozzoli R, Basso SM, D'Aurizio F, et al. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: a prospective study and literature review. Clin Biochem, 2016, 49(16-17): 1227-1231.
18. 周曉明, 康大海, 侯剛, 等. 胰島素樣生長因子結合蛋白 2 和癌胚抗原對惡性胸腔積液與結核性胸腔積液的鑒別診斷價值分析. 實用心腦肺血管病雜志, 2017, 25(1): 95-98.
19. Nguyen AH, Miller EJ, Wichman CS, et al. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res, 2015, 166(5): 432-439.
20. 陳曉波, 張琳, 徐冉冉. 腫瘤標志物 CA153、CA125 檢驗在肺癌診斷中的應用價值. 中國醫藥指南, 2018, 16(18): 142-143.
21. Chen Y, Mathy NW, Lu HD. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
22. Gu Y, Zhang M, Li GH, et al. Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax. Chin Med J (Engl), 2015, 128(3): 305-309.
23. 陳先夢, 孫耕耘. 血管內皮生長因子對惡性胸腔積液診斷價值的 Meta 分析. 中華肺部疾病雜志(電子版), 2017, 10(1): 29-34.
24. Wu DW, Chang WA, Liu KT, et al. Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion. Oncol Lett, 2017, 14(3): 3657-3662.
25. Mohajeri A, Sanaei S, Kiafar F, et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering. Adv Pharm Bull, 2017, 7(1): 21-34.
26. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab, 2006, 290(6): E1253-E1261.
27. Wali A, Morin PJ, Hough CD, et al. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer, 2005, 48(1): 19-29.
28. Tsuji S, Tsuura Y, Morohoshi T, et al. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br J Cancer, 2010, 103(4): 517-523.
29. B?ger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget, 2016, 7(17): 24269-24283.
30. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol, 2016, 17(6): 717-726.
31. Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget, 2015, 6(38): 41228-41236.
32. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol, 2015, 1(9): 1319-1323.
33. 王鵬. 血清可溶性分子 B7-H4 檢測在非小細胞肺癌中的應用. 檢驗醫學, 2013, 28(12): 1140-1141.
34. 冀玉珍, 劉曉良, 侯淼. 可溶性程序性死亡分子配體 1 在肺癌胸腔積液中的水平及臨床意義. 檢驗醫學, 2017, 32(2): 99-103.
35. 張雪漫, 王廷杰. 46 例膿胸的臨床分析和診治體會. 臨床肺科雜志, 2005, 10(2): 234.
36. 趙俊, 陳毅斐. 血清 CRP、ADA、SAA 聯合檢測在鑒別感染性胸腔積液中的價值. 醫學新知雜志, 2017, 27(5): 453-455.
37. Garcia-Pachon E, Soler MJ, Padilla-Navas I, et al. C-reactive protein in lymphocytic pleural effusions: a diagnostic aid in tuberculous pleuritis. Respiration, 2005, 72(5): 486-489.
38. Porcel JM, Bielsa S, Esquerda A, et al. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med, 2012, 23(5): 447-450.
39. 黃建達, 蔡挺. C 反應蛋白、觸珠蛋白在胸腔積液鑒別診斷中的價值. 臨床內科雜志, 2001, 18(3): 192-193.
40. Porcel JM. Pleural fluid tests to identify complicated parapneumonic effusions. Curr Opin Pulm Med, 2010, 16(4): 357-361.
41. 陳孝謙, 汪錚, 李秀. 血清降鈣素原對滲出性胸腔積液病因的鑒別價值. 臨床肺科雜志, 2013, 18(8): 1446-1448.
42. Lin MC, Chen YC, Wu JT, et al. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest, 2009, 136(1): 205-211.
43. 黃宇筠, 黃鑫炎, 羅益鋒, 等. HS-CRP、PCT 在鑒別類肺炎性與結核性胸腔積液的研究. 實用醫學雜志, 2013, 29(22): 3666-3667.
44. 邱躍靈, 麥轉英. 降鈣素原與 CA125 聯合檢測對結核性胸腔積液的診斷價值. 臨床肺科雜志, 2012, 17(9): 1640-1641.
45. He C, Wang B, Li D, et al. Performance of procalcitonin in diagnosing parapneumonic pleural effusions: a clinical study and meta-analysis. Medicine (Baltimore), 2017, 96(33): e7829.
46. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9(6): 425-434.
47. Lee J, Lee SY, Lim JK, et al. Radiologic and laboratory differences in patients with tuberculous and parapneumonic pleural effusions showing non-lymphocytic predominance and high adenosine deaminase levels. Infection, 2015, 43(1): 65-71.
48. 鄢斌, 劉軍. 聯合檢測血清及胸水 LDH、ADA、CEA、CA153 對胸水性質的鑒別價值. 現代醫藥衛生, 2009, 25(10): 1505-1507.
49. Tamiya H, Mitani A, Saito A, et al. Exosomal microRNA expression profiling in patients with lung adenocarcinoma-associated malignant pleural effusion. Anticancer Res, 2018, 38(12): 6707-6714.
50. Zennaro L, Vanzani P, Nicolè L, et al. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: a route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers. Cancer Cytopathol, 2017, 125(5): 341-348.
51. Wang C, Peng J, Kuang Y, et al. Metabolomic analysis based on ¹H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion. Mol Med Rep, 2017, 16(2): 1147-1156.

Previous Article
急性加重型慢性阻塞性肺疾病外周血生物標志物研究進展
Next Article
多器官床旁即時超聲在新型冠狀病毒肺炎中的應用：國際專家共識

Chinese Journal of Respiratory and Critical Care Medicine

生物學標志物在滲出性胸腔積液診斷的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content